Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.

TitleBreast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.
Publication TypeJournal Article
Year of Publication2017
AuthorsLiu, D, Ho, M-F, Schaid, DJ, Scherer, SE, Kalari, K, Liu, M, Biernacka, J, Yee, V, Evans, J, Carlson, E, Goetz, MP, Kubo, M, D Wickerham, L, Wang, L, Ingle, JN, Weinshilboum, RM
JournalNPJ Breast Cancer
Volume3
Pagination30
Date Published2017
ISSN2374-4677
Abstract

Our previous GWAS using samples from the NSABP P-1 and P-2 selective estrogen receptor modulator (SERM) breast cancer prevention trials identified SNPs in ZNF423 and near CTSO that were associated with breast cancer risk during SERM chemoprevention. We have now performed Next Generation DNA sequencing to identify additional SNPs that might contribute to breast cancer risk and to extend our observation that SNPs located hundreds of bp from estrogen response elements (EREs) can alter estrogen receptor alpha (ERα) binding in a SERM-dependent fashion. Our study utilized a nested case-control cohort selected from patients enrolled in the original GWAS, with 199 cases who developed breast cancer during SERM therapy and 201 matched controls who did not. We resequenced approximately 500 kb across both ZNF423 and CTSO, followed by functional genomic studies. We identified 4079 SNPs across ZNF423 and 3876 across CTSO, with 9 SNPs in ZNF423 and 12 in CTSO with p 

DOI10.1038/s41523-017-0036-4
Alternate JournalNPJ Breast Cancer
PubMed ID28856246
PubMed Central IDPMC5566425